SCHEMBL23926498

SCHEMBL23926498

CC1(C)OB(c2ccc(N3CCOCC3)c([N+](=O)[O-])c2)OC1(C)C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.55
KDM4E B2RXH2 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
LMNA P02545 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 10/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
GAA P10253 2/20 0.51
CTSB P07858 1/20 0.48
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32933259 1.00 MAPT (0.55) MAPTKDM4EL3MBTL1LMNATDP1
SCHEMBL23926530 0.90 MAPT (0.54) MAPTKDM4EL3MBTL1LMNATDP1
SCHEMBL32933328 0.90 MAPT (0.54) MAPTKDM4EL3MBTL1LMNATDP1
SCHEMBL23850805 0.89 GAA (0.63) MAPTL3MBTL1LMNATDP1MAPK1
SCHEMBL28664498 0.88 SMN1; SMN2 (0.50) MAPTKDM4EL3MBTL1LMNAMAPK1
SCHEMBL28651411 0.85 MAPT (0.49) MAPTKDM4EL3MBTL1LMNATDP1
SCHEMBL7800482 0.80 GAA (0.72) MAPTKDM4EL3MBTL1LMNATDP1
SCHEMBL13778132 0.80 MAPT (0.53) MAPTLMNATDP1MAPK1ALDH1A1
SCHEMBL790296 0.79 ALDH1A1 (0.43) MAPTKDM4EL3MBTL1LMNAALDH1A1
SCHEMBL13717675 0.79 MAPT (0.51) MAPTL3MBTL1LMNAMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 CN disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT MAPT 3061/4885KDM4E 1271/4885L3MBTL1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.